Related Experiment Video
Updated: Aug 4, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.8K
Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for
Ho Wan Chan1, Stephanie Chow1, Xinyue Zhang1
1Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2/F, Laboratory Block 21 Sassoon Road, Hong Kong S.A.R., L2-08B, Pokfulam, China.
AAPS Pharmscitech
|April 4, 2023
Summary
Inhalable nanoparticle dry powder formulations show promise for respiratory therapeutics, but clinical translation faces challenges. This review addresses research gaps in pre-clinical development to accelerate their approval and use.
Area of Science:
- Pharmaceutical Sciences
- Nanotechnology
- Respiratory Medicine
Background:
- The COVID-19 pandemic spurred interest in nanoparticle-based respiratory therapeutics.
- Dry powder inhalers (DPIs) are ideal for delivering nanoparticles due to stability and ease of use.
Purpose of the Study:
- To address the research gap in clinical translation of inhalable nanoparticle-based DPI formulations.
- To highlight overlooked issues in pre-clinical development for inhaled nanoparticle drug delivery.
Main Methods:
- Review of formulation and particle engineering strategies for inhalable nanoparticle dry powders.
- Discussion of in vitro characterization methodologies for predicting in vivo performance.
- Analysis of challenges and strategies for clinical translation.
Main Results:
- Current research has not yet led to approved inhalable nanoparticle-based DPI formulations.
- Key knowledge gaps exist in formulation, characterization, and clinical translation.
Conclusions:
- Addressing pre-clinical development gaps is crucial for advancing inhalable nanoparticle DPIs.
- Focused research can accelerate the clinical application of these next-generation respiratory therapeutics.
Related Concept Videos
01:23Inhaled Medications
331
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
331
01:17Drugs Used in Lower Respiratory Disorders: Overview
517
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
517
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:22Drug Delivery: Miscellaneous Routes
423
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
423
01:16Drugs Used in Upper Respiratory Disorders: Overview
308
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
308
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
360
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
360